格隆汇11月13日丨浙江东方(600120.SH)公布，公司全资子公司东方产融拟作为基金管理人，联合中银 资产、高新金投、浙药集团等发起设立东方浙药基金。基金募集总规模拟定5亿元，由东方产融作为控 股股东和浙药集团全资子公司汗青资本合资新设医药基金管理公司，以及中银资产全资子公司中银资本 私募基金管理（北京）有限公司（以下简称"中银资本"）分别作为执行事务合伙人GP1和GP2，各认缴 100万元，认缴比例各占0.2%。有限合伙人方面，产融慧盈认缴1.192亿元，认缴比例23.84%；浙药集团 认缴0.298亿元，认缴比例5.96%；中银资产认缴1.49亿元，认缴比例29.8%；滨江区由高新金投指定全 资子公司杭州高新（维权）创业投资有限公司（简称"高新创投"）认缴2亿元，认缴比例40%。 ...

Core Viewpoint - Zhejiang Dongfang (600120.SH) announced the establishment of the Dongfang Zheyao Fund, with a total fundraising target of 500 million yuan, aimed at investing in the pharmaceutical sector [1] Group 1: Fund Structure - Dongfang Chanyun, a wholly-owned subsidiary of Zhejiang Dongfang, will act as the fund manager [1] - The fund will be jointly established with partners including Bank of China Asset Management, High-tech Jin Investment, and Zhejiang Pharmaceutical Group [1] - The fund management company will be a joint venture between Dongfang Chanyun and a wholly-owned subsidiary of Zhejiang Pharmaceutical Group, Hanting Capital [1] Group 2: Capital Contributions - The total fundraising scale is set at 500 million yuan, with various partners contributing different amounts [1] - Limited partners include: - Chanyun Huiying: 119.2 million yuan (23.84%) - Zhejiang Pharmaceutical Group: 29.8 million yuan (5.96%) - Bank of China Asset Management: 149 million yuan (29.8%) - High-tech Jin Investment's subsidiary, Hangzhou High-tech Venture Capital: 200 million yuan (40%) [1]